Subtype
Small Cell Neuroendocrine Carcinoma
CI-CAN-00003964SCNECExplore in graph →
396 active trials6 approved drugs7 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003964SCNECExplore in graph →
Clinical trials
1,165 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (167)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07744698 | Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study)(PULSE) | recruiting | Phase 4 | 107 | Anhui Provincial Cancer HospitalOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07485920 | A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer | not yet recruiting | Phase 4 | 20 | The Affiliated Hospital of Qingdao UniversityOTHER |
| 1 |
| Mar 20, 2026 |
| clinicaltrials |
| NCT05874401 | Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan | recruiting | Phase 4 | 302 | Pharmacosmos A/SINDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT06951841 | Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction | not yet recruiting | Phase 4 | 31 | China Medical University, ChinaOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT06931145 | Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer | not yet recruiting | Phase 4 | 50 | Peking Union Medical College HospitalOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06467786 | Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer | recruiting | Phase 4 | 24 | Tang-Du HospitalOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT04180176 | Prospective Clinicogenomic Program(PCG) | completed | Phase 4 | 945 | Genentech, Inc.INDUSTRY | 1 | Jan 17, 2024 | clinicaltrials |
| NCT05071703 | Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study | completed | Phase 4 | 30 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 6, 2023 | clinicaltrials |
| NCT03890055 | Clinical Study of First-line Treatment of Small Cell Lung Cancer (SCLC) With Anlotinib Hydrochloride | unknown | Phase 4 | 30 | Chifeng Municipal HospitalOTHER | 0 | Mar 26, 2019 | clinicaltrials |
| NCT02348450 | Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer | unknown | Phase 4 | 308 | Guangdong Association of Clinical TrialsOTHER | 1 | Dec 5, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Aug 4, 2026source: clinicaltrials